[SCHEDULE 13G/A] IN8bio, Inc. SEC Filing

Rhea-AI Filing Summary

Alyeska Investment Group and related filers report beneficial ownership of warrants to purchase 89,021 shares of IN8BIO, Inc. common stock, representing 2.58% of the outstanding shares on the stated calculation basis of 3,444,234 shares. The filing shows shared voting and shared dispositive power over the 89,021 warrants, with no sole voting or dispositive power reported. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing is a joint statement by Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh, each acknowledging joint filing responsibilities.

Positive

• Disclosure of warrants totaling 89,021 shares provides transparency into Alyeska's potential economic exposure to IN8BIO
• Position is below 5% (2.58%), indicating a non-controlling interest under current calculations
• Filing certifies holdings are in the ordinary course and not intended to change control, reducing immediate governance concerns

Negative

• None.

Insights

Financial Analyst

TL;DR: Alyeska holds warrants equal to 2.58% of IN8BIO on a basic share count; stake is non-control and held in ordinary course.

The filing discloses warrants to purchase 89,021 shares, calculated as 2.58% of 3,444,234 common shares outstanding per the issuer reference. Because the position is held as warrants rather than currently outstanding shares, immediate voting dilution or ownership effects are contingent on exercise. Shared voting and dispositive power indicate the position is managed jointly through the Alyeska entities and an individual filer. The certification that the stake was not acquired to influence control reduces governance risk but does not preclude future changes if warrants are exercised.

Corporate Governance Expert

TL;DR: This is a routine Schedule 13G joint filing showing a non-control derivative position with shared authority among filers.

The document is a joint Schedule 13G amendment identifying ownership via warrants, not direct share ownership, and reports shared voting/dispositive authority for 89,021 warrants. The joint filing statement and certifications are standard for institutional and affiliated filers. Material governance implications are limited because the filing represents less than 5% and the filers assert no intent to influence control; however, exercise of warrants could alter the economic position and should be tracked against future disclosures.

08/14/2025 - 05:50 PM

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

IN8BIO, INC.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

45674E109

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 45674E109

1

Names of Reporting Persons

Alyeska Investment Group, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 89,021.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 89,021.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

89,021.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.58 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 45674E109

1

Names of Reporting Persons

Alyeska Fund GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 89,021.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 89,021.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

89,021.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.58 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 45674E109

1

Names of Reporting Persons

Anand Parekh

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 89,021.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 89,021.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

89,021.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.58 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IN8BIO, INC.
(b)	Address of issuer's principal executive offices: 350 5th Avenue, Suite 5330, New York, NY 10118
Item 2.
(a)	Name of person filing: (i) Alyeska Investment Group, L.P. (ii) Alyeska Fund GP, LLC (iii) Anand Parekh
(b)	Address or principal business office or, if none, residence: (i) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (ii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (iii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601
(c)	Citizenship: (i) Alyeska Investment Group, L.P. - Delaware (ii) Alyeska Fund GP, LLC - Delaware (iii) Anand Parekh - United States of America
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 45674E109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 89,021
(b)	Percent of class: 2.58%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 89,021
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 89,021
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alyeska Investment Group, L.P.

Signature:	Jason Bragg
Name/Title:	Jason Bragg | Chief Financial Officer
Date:	08/14/2025

Alyeska Fund GP, LLC

Signature:	Jason Bragg
Name/Title:	Jason Bragg | Chief Financial Officer
Date:	08/14/2025

Anand Parekh

Signature:	Anand Parekh
Name/Title:	Anand Parekh | Self
Date:	08/14/2025

Exhibit Information

Item 4. Ownership: The reporting persons hold warrants to purchase 89,021 shares of the Issuer's Class A common stock, par value $0.0001 per share (the "Warrants"). The percentage calculation assumes that there are currently 3,444,234 outstanding shares of Common Stock of the Issuer, based on the Issuer's Form 8-K filed with the Securities and Exchange Commission on June 4, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

FAQ

What stake does Alyeska report in IN8BIO (INAB)?

The reporting persons disclose warrants to purchase 89,021 shares, representing 2.58% of the issuer's common stock on the stated outstanding share basis of 3,444,234 shares.

Are the Alyeska filers reporting actual shares or warrants?

They report ownership of warrants to purchase 89,021 shares, not currently outstanding common shares.

Do the filers have sole voting or dispositive power over the securities?

No. The filing reports 0 sole voting power and 0 sole dispositive power, with 89,021 shared voting and 89,021 shared dispositive power.

Does the filing indicate intent to influence control of IN8BIO?

The filing includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

Which entities and individuals filed this Schedule 13G?

The joint filing is by Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh.